BioSpace News Archive

Deals

Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions

Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.

March 12, 2024
·
4 min read
Biotech Beach

Ambry Genetics Announces a Collaboration with Tempus to Advance Paired Germline and Somatic Testing Services for Medical Oncologists

Ambry Genetics announced that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services.

March 12, 2024
·
3 min read
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order

Tryp Therapeutics, Inc. is pleased to announce that the Company’s securityholders overwhelmingly approved the previously announced arrangement involving the Company and Exopharm Limited CAN 163 765 991 at the Company’s annual general and special meeting of securityholders held on March 8, 2024.

March 12, 2024
·
5 min read
Genetown

908 Devices Trace Chemical Identification Technology Adopted by European Agencies

908 Devices Inc., a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the latest in international adoption of the MX908 for trace detection and identification of priority drugs and chemical threats.

March 12, 2024
·
5 min read
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia OutbreaksA review of Russian and English literature suggests that Appili’s biodefense program ATI-1701 may have a role in preventing tularemia in Ukraine

Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia.

March 12, 2024
·
5 min read
Business

SIGA Declares Special Cash Dividend of $0.60 Per Share

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock.

March 12, 2024
·
7 min read
Business

CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CorMedix Inc. announced financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its business.

March 12, 2024
·
10 min read
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference

MaaT Pharma will present extended results from its Early Access Program for patients with aGvHD that were treated with MaaT013 and, for the first time, Overall Survival data after 12 months in more patients.

March 12, 2024
·
5 min read
OncoOne Announces Formation of Clinical Advisory Board to Support Development of ON104 for Chronic Inflammatory Diseases

OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced the formation of a clinical advisory board to provide strategic and clinical insights for the company’s lead program in immunology, ON104.

March 12, 2024
·
4 min read
Business

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024

Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system, announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2023 after the market close on Tuesday, March 19, 2024.

March 12, 2024
·
3 min read